InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026)

InMed Pharmaceuticals (INM) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. Growth (1y) (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn 61.90%
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -22.14%
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 0.46%
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 125.00%
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn 425.00%
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn -267.74%
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -18.09%
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 16.33%
10 InMed Pharmaceuticals 6.04 Mn 796,124.14 - -2.15%

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.15%
Dec 31, 2025 5.03%
Sep 30, 2025 12.00%
Jun 30, 2025 -72.81%
Mar 31, 2025 14.21%
Dec 31, 2024 -35.39%
Sep 30, 2024 15.98%
Jun 30, 2024 -56.42%
Mar 31, 2024 -16.76%
Dec 31, 2023 31.88%
Sep 30, 2023 3.61%
Jun 30, 2023 83.74%
Mar 31, 2023 69.03%
Dec 31, 2022 23.22%
Sep 30, 2022 15.01%
Jun 30, 2022 -101.75%
Mar 31, 2022 -15.99%
Dec 31, 2021 -96.17%
Sep 30, 2021 -93.49%
Jun 30, 2021 -43.43%